(c) if not, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) The Government is aware of such advertisement.

(b) and (c) This is not a medicine under Indian System of Medicine.

Development of Drug for AIDS

2672. SHRI B. J. PANDA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Ranbaxy Laboratories has developed anti-AIDS drug;

(b) if so, the details of this medicine;

(c) how far this drug has helped to control this deadly disease in our country;

(d) whether the company is exporting the drug as reported in the Hindustan Times dated 20th July, 2002;

(e) if so, the details of those countries and the foreign exchange earnings out of this, during the last two years; and

(f) the other fields where the company has excelled in medicines in the international market?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) and (b) Yes, Sir. The Ranbaxy Laboratories is licensed to manufacture/market the following anti-AIDS drugs in India:

i. Lamuvidine - 100/150 mg
ii. Lamuvidine + Zidovudine
iii. Stavudine 15/20-/30/40 mg
iv. Nevirapine 200 mg
v. Lamuvudine +Stavudine+Nevirapine
vi. Efavirenz Capsules 125/200/250/400 mg
vii. Efavirenz Tablets 600 mg.

viii. Didanosine-DR Capsules 25/50/100/200 mg.

(c) Anti-retroviral drug, Nevirapine is being used for Prevention of Mother to Child Transmission in our country and has been found to be efficacious. Besides, anti-retroviral drugs are also being adminstered for Post Exposure Prophylaxis among Health Care Workers in public sector hospitals in the event of an accidental needle/syringe injury while treating HIV/AIDS patients.

(d) and (e) the Ranbaxy Laboratories has informed that they are exporting anti-retroviral drugs to countries like Vietnam, Combodia, Brazil, Cameroon, Zambia, Nigeria, South Africa, Male, Peru and Myanmar. The detail of these countries with amount in foreign exchange earning is enclosed as Statement. (*See* below) Up to December, 2001, Ranbaxy Laboratories has reported an earning of foreign exchange of US $ 1,948,512 from dosage form. In year 2002 upto the month of June, earning of foreign exchange was reported to be US $ 666,065 from dosage form.

(f) It has been reported that the company has received regulatory approvals world wide for 325 products including 29 products in USA. Some of these products are:

MOX
NORBACIN
CIFRAN
SPORIDOR
KESLOR
ZANOCIN
ROSCILLIN
STORVAS
CALMPOSE
FORTWIN
KETANO
RICONIA
REVITAL
DOLAMIDE

Statement

Country-wise Break up (2001) with amount in foreign exchange earning through the export of anti-AIDS drug

Country	Value Rupees	Value US $
Vietnam	10,923,035	232,405
Combodia	3,364,009	71,575
Brazil	2,154,762	45,846
Cameroon	338,551	7,203
Zambia	4,202,928	89,424
Nigeria	67,379,905	1,433,615
South Africa	831,423	17,690
Male	1,445,425	30,754
Peru	809,530	17,224
Myanmar	130,491	2,776
TOTAL:	91,580,059	1,948,512

Refusal of private hospitals to treat serious cases

†2673. SHRI MOTILAL VORA: Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Government are aware that a number of private hospitals refuse to provide treatement to patients despite their serious condition due to non-payment of full amount;

(b) if so, the action Government propose to take against such private hospitals and doctors; and

(c) if not, the reasons therefor?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA): (a) to (c) Health being a State subject under the Constitution of India, regulation of private hospitals comes under the purview of the State Governments and, therefore, such information is not maintained by the Ministry of Health and Family Welfare.

†Original notice of the question was received in Hindi.